Ondansetron

Ondansetron is a selective 5-HT3 receptor antagonist that blocks serotonin signaling in the gut and brainstem regions involved in the nausea reflex. For patients on GLP-1 receptor agonist therapy, gastrointestinal side effects can occur as the digestive system adjusts to slower gastric emptying. By targeting serotonin receptors in the chemoreceptor trigger zone and vagal afferents of the gastrointestinal tract, ondansetron is designed to reduce the signaling that leads to nausea. EdgeRx offers ondansetron as a clinician-supervised, as-needed option that may be prescribed alongside GLP-1 therapy for eligible patients experiencing treatment-related nausea, as part of a broader physician-guided weight management protocol.